Yarrow Bioscience (NASDAQ:YARW – Get Free Report) and Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Analyst Recommendations
This is a summary of recent ratings for Yarrow Bioscience and Werewolf Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 121.88%. Werewolf Therapeutics has a consensus price target of $4.00, indicating a potential upside of 306.50%. Given Werewolf Therapeutics’ higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Yarrow Bioscience.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yarrow Bioscience | $570,000.00 | 122.45 | -$26.48 million | ($14.64) | -1.79 |
| Werewolf Therapeutics | $21.00 million | 2.28 | -$60.82 million | ($0.76) | -1.29 |
Yarrow Bioscience has higher earnings, but lower revenue than Werewolf Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Yarrow Bioscience and Werewolf Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
Risk and Volatility
Yarrow Bioscience has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Summary
Werewolf Therapeutics beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
-company-of-china-ltd-logo-1200x675.jpg){kind=logo}